The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer)

• Research type

  Research Study

• Full title

  The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

• IRAS ID

  135692

• Contact name

  Susana Banerjee

• Contact email

  susana.banerjee@rmh.nhs.uk

• Sponsor organisation

  Array BioPharma Inc.

• Eudract number

  2013-000277-72

• Clinicaltrials.gov Identifier

  NCT01849874

• Research summary

  Summary of Research
  A phase III international study to find out if the study medicine, MEK162, is safe and has beneficial effects in people who have a rare form of cancer in the ovaries, fallopian tube or primary peritoneum. Participants will either receive MEK162 or their physician’s choice of selected chemotherapies approved for the use of ovarian cancer.

  Approximately 300 female participants over the age of 18 meeting eligibility will be recruited globally. Participants are expected to receive study drug for up to 12 months.

  The study is being funded by Array BioPharma Inc.

  Summary of Results
  https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbVtiUO83io7x4WP0JR0wpUEUa9LVIjzct2HBfE00rQsxW5neFFW1bQaPSm58PYp3GRVzcZNqJx99p6mVnI4xDgUX-2B5etu5u-2Bunf6XVYi-2BQSKN3S-2BoV9Lv-2BjN8CEw1EtjA37uC5yFJvnWQgox6HV-2FzDpVvNZgA-2FgvV7kKbCmT45nCHahj_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YKbsV6O0VlvMMBv3ArHqXfBNWTjSzsl-2B-2Fb6UgmYK0zzOayO51jNjM-2BvQQVIU1uD9E5qKKFXMWnSBz31jXdk4i6n9r1ScFIjW8230v1EZ-2BHx2kPIMI3VePWZvl2vOhMvbt7zyuH49egh0Jfi9MrJeCwW-2F8oaVCne11CpJyt3KVHJNg-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7Cf3a4be5d665c4998a01608db2ecea829%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638155237339819221%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=dTUeoFy6e4z7Ioki5x22WvG8NEC%2Bn9%2FVCO%2BDaypYCAA%3D&reserv

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  13/LO/1252

• Date of REC Opinion

  8 Oct 2013

• REC opinion

  Favourable Opinion